Camizestrant significantly improved progression-free survival (PFS) compared to fulvestrant in patients with estrogen receptor (ER)-positive, HER2-negative breast cancer ... The objective response ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

The following is a summary of “Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage ...

Professor Angela, Leung Yee-man, Associate Head (Research) of the School of Nursing at The Hong Kong Polytechnic University; ...

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) to report its financial ...

Tizona Therapeutics has expanded its ongoing Phase Ib clinical trial of TTX-080, HLA-G, in patients with biomarker-defined ...

In the new arms, patients with certain biomarker-defined tumors will receive either an HLA-G targeted antibody, chemo, and Erbitux, or just chemo and Erbitux.

Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus ...

CIDRAP: Paxlovid Tied To Fewer COVID-19 Hospitalizations, Reduced Risk Of Long COVID A new retrospective cohort study conducted in Dubai shows that the antiviral nirmatrelvir plus ritonavir, ...

Vyloy plus standard-of-care chemotherapy extended overall survival in patients with advanced gastric cancer. The rate of ...

Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding ...

New research unveiled in the Journal of the National Comprehensive Cancer Network (JNCCN) highlights significant benefits of ...